Oral Contraceptives and Plasma Lipoprotein Metabolism

  • Ronald M. Krauss
  • Diane L. Tribble
Part of the Clinical Perspectives in Obstetrics and Gynecology book series (CPOG)


While the relationship of oral contraceptive (OC) use to cardiovascular disease (CVD) is likely to be multifactorial, OC effects on plasma lipid and lipoprotein metabolism are potentially important.1,2 Commonly used OC preparations result in elevations in plasma triglycerides (TG), very low-density lipoproteins (VLDL) and low-density lipoproteins (LDL), and reductions in high-density lipoproteins (HDL), particularly the HDL2 subclass. In this chapter, hormonally mediated lipid and lipoprotein metabolic alterations and effects of commonly used combination OC preparations are described within the general context of lipoprotein metabolism and the relationship of lipoprotein parameters to CVD.


Oral Contraceptive HDL2 Subclass Hepatic Lipase Activity Lipoprotein Change Combination Oral Contraceptive 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Slone D, Shapiro S, Kaufman DW. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981; 305: 420–424.PubMedCrossRefGoogle Scholar
  2. 2.
    Stadel BW. Oral contraceptives and cardio-vascular disease. N Engl J Med 1981; 305: 672–677.PubMedCrossRefGoogle Scholar
  3. 3.
    de Graaf J, Hak-Lemmers HLM, Hectors MPC, Denmarcker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscl Thromb 1991; 11: 298.PubMedCrossRefGoogle Scholar
  4. 4.
    Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189–199.PubMedCrossRefGoogle Scholar
  5. 5.
    Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. J Am Med Assoc 1988; 260: 1917.CrossRefGoogle Scholar
  6. 6.
    Musliner T, Krauss RM. Lipoprotein subspecies and risk of coronary disease. Clin Chem 1988; 33: B78–B83.Google Scholar
  7. 7.
    Ohta T, Takata K, Horiuchi S, et al. Protective effects of lipoproteins containing apoprotein A-I on Cu2 + -catalyzed oxidation of human low density lipoprotein. FEBS Lett 1989; 257: 435–438.PubMedCrossRefGoogle Scholar
  8. 8.
    Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta 1990; 1044: 275–283.PubMedGoogle Scholar
  9. 9.
    Gianturco SH, Bradley WA. Triglyceride-rich lipoproteins and their role in atherogenesis. Curr Opin Lipidol 1991; 42: 324–328.CrossRefGoogle Scholar
  10. 10.
    Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325: 1196–1204.PubMedCrossRefGoogle Scholar
  11. 11.
    Tikkanen MJ, Nikkila EA. Oral contraceptives and lipoprotein metabolism. J Reprod Med 1986; 31: 898–905.PubMedGoogle Scholar
  12. 12.
    Schaefer EJ, Foster DM, Zech LA, et al. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal fe-males. J Clin Endocrinol Metab 1983; 57: 262–267.PubMedCrossRefGoogle Scholar
  13. 13.
    Applebaum D, Goldberg AP, Pykalisto OJ. et al. Effects of estrogens on post-heparin lipolytic activity. Selective decline in hepatic triglyceride lipase. J Clin Invest 1977; 59: 601–608.PubMedCrossRefGoogle Scholar
  14. 14.
    Tikkanen MJ, Nikkila EA, Kuusi T, et al. High density lipoprotein-2 and hepatic lipase: reciprocal changes produced by estrogen and norgestrol. J Clin Endocrinol Metab 1981; 54: 1113.CrossRefGoogle Scholar
  15. 15.
    Dorflinger LJ. Relative potency of progestins used in oral contraceptives. Contraception 1985; 31: 557–570.PubMedCrossRefGoogle Scholar
  16. 16.
    Spellacy WN. Carbohydrate metabolism in male infertility and female-fertility control patients. Fertil Steril 1976; 27: 1132–1141.PubMedGoogle Scholar
  17. 17.
    Wahl P, Waiden C, Knopp R, Hoover J. Effect of estrogen/progestin potency on lipid/ lipoprotein cholesterol. N Engl J Med 1983; 308: 862–867.PubMedCrossRefGoogle Scholar
  18. 18.
    Perlman JA, Krauss RM, Ray R, et al. Smoking, oral contraceptives, and other risk factors for atherosclerotic heart disease. In Rosenberg M (ed): Smoking and Reproductive Health. New York, Praeger Medical, 1987; 27–35.Google Scholar
  19. 19.
    Godsland IF, Crook D, Simpson R, Proudler T, Felton C, Lees B, Anyaoku V, Devenport M, Wynn V. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–1381.PubMedCrossRefGoogle Scholar
  20. 20.
    Godsland IF, Crook D, Wynn V. Coronary heart disease risk markers in users of low-dose oral contraceptives. J Reprod Med 1991; 36: 226–237.PubMedGoogle Scholar
  21. 21.
    Lipson A, Stoy DB, LaRosa JC. et al. Progestin and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception 1986; 34: 21–134.CrossRefGoogle Scholar
  22. 22.
    Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstet Gynecol 1988; 71: 33–38.PubMedGoogle Scholar
  23. 23.
    Krauss RM, Roy S, Mishell DR Jr, et al. Effects of low-dose oral contraceptives on serum lipids and lipoproteins: differential changes in high density lipoprotein subclasses. Am J Obstet Gynecol 1983; 145: 446–452.PubMedGoogle Scholar
  24. 24.
    Lussier-Cacan S, Nestruck AC, Arslanian H, Xhignesse M, Davignon J, Kafrissen ME, Chapdelaine A. Influence of a triphasic oral contraceptive preparation on plasma lipids and lipoproteins. Fertil Steril 1990; 53: 28–34.PubMedGoogle Scholar
  25. 25.
    Bringer J. Norgestimate: a clinical overview of a new progestin. Am J Obstet Gynecol 1992; 66: 1969–1977.Google Scholar
  26. 26.
    Kuusi T, Nikkila EA, Tikkanen MJ, Sipinen S. Effects of two progestins with different androgenic properties on hepatic endothelial lipase and high density lipoprotein 2. Atherosclerosis 1985; 54: 251–262.PubMedCrossRefGoogle Scholar
  27. 27.
    Kauppinen-Makelin R, Kuusi T, Ylikorkala O, Tikkanen MJ. Contraceptives containing desogesterol or levonorgestrel have different effects on serum lipoproteins and post-heparin plasma lipase activities. Clin Endocrin 1992; 36: 203–209.CrossRefGoogle Scholar
  28. 28.
    Fioretti P, Fruzetti F, Navalesi R, et al. Clinical and metabolic study of a new pill containing 20 meg ethinylestradiol plus O.150 meg desogestrol. Contraception 1987; 35: 229–243.PubMedCrossRefGoogle Scholar
  29. 29.
    Ylikorkala O, Kuusi T, Tikkanen MJ, et al. Desogestrol- and levonorgestrel-containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab 1987; 65: 1238–1242.PubMedCrossRefGoogle Scholar
  30. 30.
    Krauss RM. Contraceptive steroid effects on serum lipoproteins and lipoprotein subclasses. In Blye R, Gregiore A (eds): Contraceptive Steroids: Pharmacology and Safety. New York, Plenum Publishers, 1986; 321 - 338.Google Scholar

Copyright information

© Springer-Verlag New York, Inc. 1993

Authors and Affiliations

  • Ronald M. Krauss
  • Diane L. Tribble

There are no affiliations available

Personalised recommendations